GPCR
Structure Therapeutics, Inc. Sponsored ADR · NASDAQ
- Sector Commercial Services
- Industry Miscellaneous Commercial Services
- Website ructuretx.com
- Employees(FY) 87
- ISIN US86366E1064
Performance
-6.47%
1W
-4.42%
1M
-21.07%
3M
-24.61%
6M
-11.31%
YTD
+55.68%
1Y
Profile
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Investment Analysis Report: GPCR
Overview
GPCR is a company in the Commercial Services sector, specifically in the Miscellaneous Commercial Services industry. The company has a market capitalization of $2.09 billion. In this report, we will conduct a comprehensive analysis of GPCR's financial statements over the past three years, including the b...
Technical Analysis of GPCR 2024-05-10
Overview:
In analyzing the technical indicators for GPCR over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-09 16:05
- 2024-05-09 10:56
- 2024-05-09 10:34
- 2024-05-09 04:05
- 2024-04-24 06:33
- 2024-03-30 09:37
7 Small-Cap Stocks that Wall Street Loves for Good Reason(InvestorPlace)
- 2024-03-14 22:53
- 2024-03-10 09:08
- 2024-03-08 16:05
- 2024-03-08 08:30
- 2024-03-08 03:05
- 2024-03-07 19:30
- 2024-01-22 05:24
Here’s Why Structure Therapeutics (GPCR) Fell in Q4(Insider Monkey)
- 2024-01-21 16:24
Here's Why Structure Therapeutics (GPCR) Fell in Q4(Insidermonkey)
- 2023-12-25 07:45
- 2023-12-22 16:21
7 Small-Cap Stocks That Wall Street Loves for Good Reason(InvestorPlace)
- 2023-12-18 16:06
Structure Plummets 43% After Trailing Lilly In Obesity Treatment(Investor's Business Daily)
- 2023-12-18 13:03
Another Drugmaker Hits Rocks Seeking a Weight-Loss Pill(The Wall Street Journal)
- 2023-12-18 11:29
- 2023-12-18 07:30
- 2023-12-18 07:30
- 2023-12-18 06:23
- 2023-12-17 20:22
- 2023-12-17 18:30
- 2023-12-10 23:26
- 2023-11-29 02:30
11 Best Young Stocks to Buy and Hold For 20 Years(Insider Monkey)
- 2023-11-29 01:28
- 2023-11-27 09:50
11 Best Upside Stocks To Buy Right Now(Insider Monkey)
- 2023-11-26 03:44
2 Biotech Stocks That Could Soar in December(Yahoo Finance)
- 2023-11-14 03:10
Page 1 of 2
previousnext